drugset / Trial / NCT00865436

A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions

NCT00865436

Phase 1 Completed 36 enrolled Actavis Inc.
RandomizedCrossoverOpen-label

Summary

The purpose of this study is compare the relative bioavailability of 5 mg Glyburide/500 mg Metformin Hydrochloride Tablets by Alpharma with that of 5 mg/500 mg CLUCOVANCE® Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 5 mg/500 mg tablet) in healthy adult volunteers administered under fasting conditions.

Timeline

Start
2004-04
Primary completion
2004-04
Completion
2004-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Glyburide Small molecule 5 mg Oral
Subject Metformin Small molecule 500 mg Oral

Indications

No indication recorded.